Between The Lines

CRESTONE: Initial Efficacy and Safety of Seribantumab in Solid Tumors Harboring NRG1 Fusions

July 7th 2022

Expert oncologists review key data from the CRESTONE trial, which observed the safety and efficacy of seribantumab, an anti-HER3 IgG2 monoclonal antibody, in solid tumors with NRG1 fusions.

US Physician Paradigm Study Informs Decision-Making in Locally Advanced/Metastatic Urothelial Carcinoma

July 7th 2022

Shilpa Gupta, MD, and Vinit Makkar, MD, discuss the treatment patterns and disease management of locally advanced/metastatic urothelial carcinoma, with a focus on data from the US physician-based PARADIGM study.

Between The Lines: Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

May 16th 2022

Michael R. Bishop, MD, and Bruce B. Bank, MD, review results from the ELEVATE-RR noninferiority trial on acalabrutinib versus ibrutinib in CLL, and discuss the clinical implications of the findings.

Utility of ctDNA to Manage Adjuvant Therapy in CRC Based on Results of the GALAXY Study

May 5th 2022

Stacy A. Cohen, MD, and Mark Lewis, MD review results from the GALAXY study on circulating tumor DNA dynamics in CRC that were recently presented at ASCO GI 2022, and discuss the clinical implications of the findings.

Updates in Use of Proteasome Inhibitors for Relapsed/Refractory Multiple Myeloma

March 21st 2022

Expert perspectives on recent updates in the use of proteasome inhibitors for patients with multiple myeloma.

Reviewing Data on Lenvatinib plus Pembrolizumab Combination Treatment for Advanced Renal Cell Carcinoma

March 17th 2022

A panel of oncologists reviews a publication by Motzer et al. (2021) on data from the CLEAR trial studying lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma treatment and discuss the clinical implications of the results.

Mobocertinib Use in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive mNSCLC

March 4th 2022

Expert oncologists review safety/efficacy data behind mobocertinib, a small molecule tyrosine kinase inhibitor, in patients with EGFR exon 20 insertion–positive metastatic non–small cell lung cancer.

Routine Clinical Practice Comparison of IRD and Rd in RR Multiple Myeloma

January 19th 2022

Suzanne Fanning, DO, and Joshua Richter, MD, discuss clinical implications of a real-world study of ixazomib, lenalidomide, and dexamethasone compared with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.

The Role of Apalutamide in Patients with Metastatic Castration-Sensitive Prostate Cancer

December 23rd 2021

Neeraj Agarwal, MD, and Simon Chowdhury, MD, review final results from the TITAN study of apalutamide in patients with mCSPC and discuss the clinical implications of the findings.

Ponatinib Dose-Ranging Study in Chronic-Phase Chronic Myeloid Leukemia

December 22nd 2021

Experts discuss use of ponatinib in chronic myeloid leukemia and optimal dosing.